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Abstract Osteoarthritis is a syndrome affecting a variety
of patient profiles. A European Society for Clinical and
Economic Aspects of Osteoporosis and Osteoarthritis and
the European Union Geriatric Medicine Society working
meeting explored the possibility of identifying different
patient profiles in osteoarthritis. The risk factors for the
development of osteoarthritis include systemic factors
(e.g., age, sex, obesity, genetics, race, and bone density)
and local biomechanical factors (e.g., obesity, sport, joint
injury, and muscle weakness); most also predict disease
progression, particularly joint injury, malalignment, and
synovitis/effusion. The characterization of patient profiles
should help to better orientate research, facilitate trial de-
sign, and define which patients are the most likely to
benefit from treatment. There are a number of profile
candidates. Generalized, polyarticular osteoarthritis and
local, monoarticular osteoarthritis appear to be two dif-
ferent profiles; the former is a feature of osteoarthritis co-
morbid with inflammation or the metabolic syndrome,
while the latter is more typical of post-trauma os-
teoarthritis, especially in cases with severe malalignment.
Other biomechanical factors may also define profiles, such
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as joint malalignment, loss of meniscal function, and
ligament injury. Early- and late-stage osteoarthritis appear
as separate profiles, notably in terms of treatment response.
Finally, there is evidence that there are two separate pro-
files related to lesions in the subchondral bone, which may
determine benefit from bone-active treatments. Decisions
on appropriate therapy should be made considering clinical
presentation, underlying pathophysiology, and stage of
disease. Identification of patient profiles may lead to more
personalized healthcare, with more targeted treatment for
osteoarthritis.
Key Points
A range of factors affect pathogenesis, presentation,
and prognosis of osteoarthritis.
These factors could have an impact on response to
symptomatic or structural treatments for
osteoarthritis.
There is some evidence that patients with early
disease respond better to pharmacological treatments
for osteoarthritis than those with late disease.
Treatment decisions should be made considering
clinical presentation, underlying pathophysiology,
and the stage of disease.
1 Introduction
Osteoarthritis is progressive chronic disease potentially
affecting every articular tissue, and may potentially lead to
joint failure. It has heterogeneous manifestations, and does
not always have the same appearance in all patients. In-
deed, osteoarthritis may present differently in men and
women [1, 2], in patients with or without trauma, in ath-
letes, or in obese patients. This raises the possibility that
osteoarthritis patients with different profiles could require
different treatments.
The European Society for Clinical and Economic
Aspects of Osteoporosis and Osteoarthritis (ESCEO) has
already explored a variety of pivotal issues in osteoarthritis,
including the question of how best to define responders to
treatment for drug development [3], and the value of
biomarkers and magnetic resonance imaging (MRI) in the
diagnosis of the disease and the prediction of the hard
outcome of joint replacement surgery [4, 5]. In a new
meeting in October 2013, an ESCEO–EUGMS (European
Union Geriatric Medicine Society) working group dis-
cussed the possibility of identifying patients who would
benefit most from treatment for osteoarthritis. The hy-
pothesis discussed was that there may be different patient
profiles according to mechanical or systemic features of the
disease, or stage of the disease. This may have a variable
impact on how patients react to treatments, and possibly
even provide an explanation for the failure of clinical trials
in osteoarthritis. Indeed, personalized medicine may prove
to be advantageous in osteoarthritis insofar as it is a
heterogeneous disease, with variable progression, and there
is no standardized treatment that works in all patients [6].
The ultimate aim of these discussions is to lead to a more
personalized clinical approach and cost-effective care for
patients with osteoarthritis. This article is a summary of
these discussions.
2 Process and Outcomes
We identified relevant articles, reviews, and abstracts in a
search of PubMed/MEDLINE and EMBASE for English-
language articles published between 1990 and October
2013. The initial search strategy included the terms os-
teoarthritis, risk factor, predictor, progression, guidelines,
biomarkers, MRI, and phenotype, and yielded 463 items.
Separate subsearches were also performed using a cross-
search of the above terms combined, and additional refer-
ences were selected from the reference lists of selected
articles and the presentations made during the working
meeting. The narrative is therefore largely based upon
expert opinion. Overall, 73 relevant items were selected by
the authors according to their quality and pertinence for
discussion by the ESCEO working group.
2.1 Epidemiology and Risk Factors for Progression
The general definition of osteoarthritis is a group of over-
lapping disorders with similar structural and clinical out-
comes [7]. Indeed, osteoarthritis can affect articular
cartilage, subchondral bone, synovium, meniscus, muscle,
capsule, and ligaments. This definition of osteoarthritis
may be important for the characterization of patient pro-
files, since it determines what sort of information is to be
captured, i.e., structural, clinical, or surgical. Osteoarthritis
has been classified into three subsets according to distinct
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etiological, clinical, and therapeutic characteristics: estro-
gen deficiency-related, genetically-induced, and age-relat-
ed (Fig. 1) [1, 2]. This proposal is based on the etiology
and pathogenesis of osteoarthritis [2], and combines the
three main biological processes crucial for the development
of osteoarthritis, together with additional risk factors such
as obesity, the metabolic syndrome, and trauma. Under-
standing the pathogenesis of the disease is important for
determining patient profiles in order to establish rational
treatment in osteoarthritis. Another important consideration
is that osteoarthritis is usually an insidiously progressive
disease, and a patient’s profile may evolve over the course
of the disease [8]. It has been proposed that all of the
clinical forms are interchangeable in the early stages of
disease and may appear as differing clinical profiles in
various tissues [9]. In more advanced disease, clinical and
imaging presentations become more generalized and pro-
files may overlap.
In the research setting, osteoarthritis is generally clas-
sified radiographically, most typically using the Kellgren–
Lawrence (KL) grading system [10, 11]. Although the
correlation is not always linear [12, 13], the osteoarthritis
patients with the most pain tend to have the highest KL
grades.
Osteoarthritis has a high incidence. A recent study in a
Spanish population including more than 3 million indi-
viduals reported incidence rates of clinically diagnosed
osteoarthritis of 6.5, 2.1, and 2.4 per 1,000 person-years for
knee, hip, and hand, respectively [14]. The incidence of
osteoarthritis increases with age, rising sharply beyond the
age of 50 years and leveling off after the age of 80 years
[7, 14–16]. It is considerably more common in women than
in men [7, 15, 16]. For example, in the Spanish study, the
incidence rate of knee osteoarthritis in women was 8.3 per
1,000 person-years versus 4.6 per 1,000 person-years for
men [14]. In view of the high prevalence and high cost of
the surgical consequences of joint failure, osteoarthritis
constitutes a major healthcare burden. The situation may
even be worsening, since the rates of total hip replacement
have increased and there are signs that joint replacement
may be occurring at an earlier age [17]. The notion of
healthcare burden is also important since patients with
osteoarthritis are at higher risk for mortality than the gen-
eral population, and there have been calls for a more uni-
fied approach to healthcare in these patients, including
effective management of cardiovascular risk factors and
co-morbidities [18, 19].
There are many risk factors for osteoarthritis, including
systemic factors, such as age, sex, body mass index (and
obesity), genetic factors, bone density, and estrogen status,
and local biomechanical factors, such as obesity, physical
activity or occupation, intense sporting activity, joint injury
or deformity, and muscle weakness [7]. Some of these are
also risk factors for progression of the disease. The three
risk factors that appear to most consistently predict pro-
gression are obesity, generalized osteoarthritis, and
Fig. 1 Three subsets of osteoarthritis with distinct etiological, clinical, and therapeutic characteristics. Adapted from Herrero-Beaumont et al.
[2], with permission
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synovitis/effusion [20]. Joint space narrowing over 5 years
has recently been demonstrated to predict future knee re-
placements up to 15 years later [21, 22]. There are many
epidemiological studies on progression of osteoarthritis. In
one analysis performed in the Chingford Women’s Study
[23], the progression of radiographic knee osteoarthritis,
i.e., KL grade, was recorded in a sample of 561 patients.
Although more than half of patients had no progression
with stable KL grades over 15 years, patients with KL
grade 1 were twice as likely to progress as those with KL
grade 0 [24]. While the evidence points to a rapid pro-
gression of patients with early disease, it should be treated
with caution due to the possibility of collider bias, which is
a potential confounder in any analysis involving selection
of patients at baseline on the basis of a characteristic that is
also a risk factor.
Current treatment guidelines in osteoarthritis generally
agree that it requires a combination of non-pharmaco-
logical and pharmacological modalities [25–31]. Manage-
ment should start with non-pharmacological therapy, and if
symptoms persist a stepwise increase in treatment intensity
should follow, starting with over-the-counter treatments,
then prescription treatments for pain control, and then, if
needed, referral for surgery; opioid analgesics are generally
reserved for patients who cannot receive surgery. Regula-
tory guidelines are also available for drug development in
the symptomatic and structural management of os-
teoarthritis [32]. None of these guidance documents pro-
vide any information on which patients should be treated.
2.2 Identification of Patient Profiles in Osteoarthritis
The characterization of patient profiles appears as an im-
portant priority for osteoarthritis for a number of reasons.
First, it would help to better orientate research and un-
derstand the disease, which would in turn improve its
management. Second, it would facilitate the design of
randomized clinical trials in the field and the development
of new pharmacological strategies. Third, it would help to
better determine which patients are the most likely to
benefit from which treatment, leading to more personalized
medicine and more effective use of healthcare [6].
Osteoarthritis is a heterogeneous disorder and the var-
ious patient profiles will be influenced by many different
factors (Table 1), all of which may impact response to
treatment and some of which are interdependent. These
include factors related to morphology and anatomy, the
type of tissue that is affected, the presence of co-mor-
bidities, and the clinical presentation.
The identification of patient profiles will necessarily
involve the use of biomarkers and imaging markers, as has
been discussed previously by the ESCEO [4, 5]. Although
there are a number of promising candidates for biomarkers
[5, 33, 34], such as urinary C-terminal telopeptide of col-
lagen type II (CTX-II) and serum cartilage oligomeric
protein (COMP), none is sufficiently discriminating for
diagnosis or prediction of prognosis in patients or for use as
a surrogate outcome in clinical trials. As regards imaging,
radiographic joint space width or narrowing remain the
recommended parameters according to the regulatory
bodies [35]. On the other hand, MRI markers also provide a
good measure of cartilage morphometry [4, 36], meniscal
damage [37], bone marrow lesion [37], and synovial ef-
fusion [38, 39].
2.2.1 Profiles According to Articular Involvement: Local
or Generalized Inflammation-Driven Osteoarthritis
Generalized osteoarthritis may be a different profile from
local osteoarthritis. The term ‘generalized osteoarthritis’ is
widely used in the literature with a variety of conflicting
definitions [40]. In the context of our discussion, we con-
sider generalized osteoarthritis as representing a systemic
disease affecting a number of different joints at the same
time, i.e., it is polyarticular. This is a feature of os-
teoarthritis co-morbid with inflammation or the metabolic
syndrome. On the other hand, local osteoarthritis occurs in
a single joint, i.e., it is monoarticular, and is typical of post-
traumatic osteoarthritis. It could be surmised that biologi-
cal markers would be more suitable for identification of the
profile of generalized osteoarthritis, while imaging markers
Table 1 Possible factors influencing patient profile in osteoarthritis,
which might also affect response to treatment
Morphology and anatomy (biomechanical aspects)
Local vs. generalized disease
Monoarticular vs. polyarticular disease
Alignment (or lack thereof)
Ligamentous laxity
Trauma
Location (hand/knee vs. hip)
Femoropatellar joint vs. tibiopatellar joint
Tissue affected
Bone vs. cartilage vs. synovium
Subchondral bone osteopenia vs. subchondral bone sclerosis
Co-morbidities
Obesity
Metabolic syndrome
Osteoporosis
Clinical presentation
Symptoms (pain) vs. structure
Early- vs. late-stage disease
Inflammation
Age
Male vs. female
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would be more effective for exploration of local effects
post-trauma. Similarly, within the range of biomarkers,
serum measurements may provide a better measure of
generalized osteoarthritis (cartilage and bone sources),
while intra-articular biomarkers may better characterize
local osteoarthritis [41, 42]. Ongoing genetic studies in
more than 2,500 patients with generalized osteoarthritis are
set to detect linkage of circulating biomarkers to os-
teoarthritis-associated genes, and may shed further light on
the possibilities of genetic profiling for the disease [43].
There is contradictory evidence surrounding the role of
inflammation, with reports that serum high-sensitivity
C-reactive protein may or may not be associated with
structural progression and symptoms [44–48]. An alterna-
tive explanation is that this is related to a high body mass
index or the presence of the metabolic syndrome.
2.2.2 Early Versus Late: Profiles According to Structural
Damage and Response to Treatment
Patients in the early stages of osteoarthritis, i.e., those
with less severe disease, may have a separate profile from
patients with advanced osteoarthritis, i.e., those with very
severe disease. This is an important point since there is
evidence that response to treatment may depend on a
number of factors related to severity, e.g., extent of
structural damage or the site of osteoarthritis (hand, knee,
or hip). A dedicated PubMed search using ‘‘predictor’’ as
a MeSH term yielded 13 studies on predictors of response
in knee osteoarthritis (Table 2) (including five studies in a
single systematic review on steroid injection) [49–57]. All
of the studies involved assessment of structure via ra-
diography, usually with some evaluation of symptoms.
They cover a wide variety of potential treatments in-
cluding doxycycline, weight loss, cindunistat, corticos-
teroid injection, chondroitin sulphate, glucosamine, and
celecoxib. The overall conclusion from the studies is that
patients with the least severe knee osteoarthritis (i.e.,
those with the largest joint space width early disease or
with a low KL grade) are more likely to benefit from
effective treatment than those with more severe disease (a
smaller joint space width or higher KL grade). This im-
plies that the most powerful predictor of treatment re-
sponse is severity of osteoarthritis, with the least
symptomatic patients, i.e., those with early stage disease,
likely to have the best response to treatment. Patients with
more advanced osteoarthritis, with extensive structural
damage to the joint or malalignment, appear less likely to
respond.
There are a number of methodological issues with the
studies included in Table 2 (e.g., heterogeneity of the data,
small studies, low statistical power, placebo effects,
Table 2 Studies in knee osteoarthritis assessing predictors of response to treatment
References Treatment being tested Patients;
duration
Main
evaluation
Conclusion
Mazzuca
et al. [49]
Doxycycline 379 patients; 16
months
Radiography Patients with neutral joint structure at baseline respond
better to treatment than those with varus malalignment
Gudbergsen
et al. [50]
Weight loss 30 patients;
32 weeks
MRI/
radiography
Baseline joint structure did not correlate with symptomatic
progression
Gudbergsen
et al. [51]
Weight loss 175 patients; 16
weeks
MRI/
radiography
Radiographic grade did not predict response to
symptomatic relief
Hellio le
Graverand
et al. [52]
Cindunistat 1,457 patients;
2 years
Radiography Patients with less severe OA (KL grade 2) at baseline were
more responsive to treatment than those with more severe
disease (KL grade 3)
Maricar
et al. [53]
Corticosteroids Systematic
review (5
studies)
Radiography Radiographic severity was a predictor (2 studies): the more
severe the OA, the less likely the patient was to have
symptomatic response
Radiographic OA grading did not predict response (2
studies)
Arthroscopic cartilage grading was not linked to response
(1 study)
Sawitzke
et al. [54]
Chondroitin sulphate,
glucosamine, and
celecoxib
572 patients;
2 years
Radiography Patients with mild OA (KL grade 2) at baseline responded
better to treatment than patients with higher KL grade
Bennett
et al. [55]
Glucosamine sulphate 39 patients;
12 weeks
Radiography Patients with less severe OA at baseline had a better
symptomatic response to treatment
Bruye`re
et al. [56, 57]
Glucosamine sulphate 212 patients;
3 years
Radiography Patients with less severe OA at baseline had the most
dramatic progression of disease
KL Kellgren–Lawrence, MRI magnetic resonance imaging, OA osteoarthritis
Identifying Patients to Treat in Osteoarthritis 183
regression to the mean, confounding factors, ceiling effects
with the use of radiography, and collider bias). These ob-
servations therefore require careful interpretation and fur-
ther research to ascertain the validity of any conclusion.
2.2.3 Profiles According to the Biomechanical Properties
of the Joint
There is an increasing weight of evidence that biome-
chanical aspects may affect the incidence and progression
of osteoarthritis [58, 59]. One example of this comes from
an MRI study, which indicated that the presence of cam
deformity femoroacetabular impingement appeared to
predict the onset of hip osteoarthritis [60]. The most im-
portant contributors to progression appear to be joint
malalignment, loss of meniscal function, and ligament in-
jury, and so it is likely that the same biomechanical aspects
could also determine response to treatment. Other me-
chanical factors such as joint injury, obesity, and sport may
also play a role [61, 62]. This raises the possibility of
different profiles according to joint morphology and
biomechanical function.
Biomechanical factors should be taken into account in
the management of osteoarthritis. For example, correction
of malalignment using a wedge insole has been reported to
be highly effective in relieving pain and function in valgus
knee osteoarthritis [63]. Similarly, use of a medial collagen
meniscus implant in patients with meniscus injuries was
shown to improve pain, activity, and radiological outcomes
over 10 years compared with patients with partial medial
meniscectomy [64]. There is also evidence that deformity
or malalignment could have an effect on the efficacy of
treatments for osteoarthritis. In one of the studies in
Table 2, patients with neutral joint structure at baseline
responded better to the structural effects of treatment with
doxycycline than those with varus malalignment [49].
2.2.4 Profiles According to the Role of the Subchondral
Bone
There is evidence that there are two separate patient pro-
files related to lesions in the subchondral bone. Although
alterations in the subchondral bone appear to play a crucial
role in the development and progression of osteoarthritis
[65], the literature on the relationship between os-
teoarthritis and osteoporosis remains mixed on the subject
[66–68]. We should recall that despite increase bone vol-
ume fraction, subchondral bone is hypomineralized and of
inferior quality in osteoarthritis. One hypothesis is that the
subchondral bone remodeling observed in osteoarthritis is
different from that in osteoporosis [69, 70]: increased bone
mineral density (i.e., increased bone formation) is associ-
ated with subchondral bone sclerosis, while decreased bone
mineral density (i.e., increased resorption) is associated
with subchondral bone osteopenia. Animal experiments
indicate that osteoporosis aggravates the progression and
severity of osteoarthritis [71, 72], possibly due to sub-
chondral bone fragility [73, 74].
The presence of two patient profiles may have direct
implications for the effect of bone-active treatments in
osteoarthritis. Indeed, response to treatment may vary ac-
cording to whether the subchondral bone lesion has a
sclerosis phenotype or an osteoporotic phenotype [75, 76],
and patients with the osteoporotic profile could gain more
benefit from bone-active treatments [69, 77–79]. More re-
search into this is necessary, especially since varying re-
sults have been found with antiresorptive agents in
osteoarthritis [80, 81]. On the other hand, subchondral bone
mineral density should be assessed in osteoporosis patients
with other risk factors for osteoarthritis in order to establish
an early treatment [76].
3 Discussion
Osteoarthritis is a complex disease with varying influences
on its natural history. There is currently a strong promise of
therapeutic intervention. A range of factors affect its
pathogenesis, presentation, and prognosis: joint mor-
phology and anatomy, the specific type of tissue affected,
the presence of co-morbidities, and the clinical presenta-
tion (Table 2). All of these factors could have an impact on
response to symptomatic or structural treatments for os-
teoarthritis, leading to the possibility that different patient
profiles have differing responses. Further research is nec-
essary in the field before this can be applied in clinical
practice.
We have explored the various possible patient profiles in
osteoarthritis. The most logical pair of profiles is general-
ized osteoarthritis (i.e., polyarticular or systemic disease,
which may be linked to inflammatory disorders or the
metabolic syndrome) and local osteoarthritis (i.e.,
monoarticular, which is more likely in post-trauma patients
or in cases of malalignment). While this separation is clear
in clinical practice, i.e., the post-trauma patient presents
very differently from the metabolic syndrome patient,
whether they respond in the same manner to pharmaco-
logical treatments for osteoarthritis remains an issue for the
research agenda.
By contrast, there is some evidence that patients with
early disease respond better to pharmacological treatments
for osteoarthritis than those with late disease. Further re-
search is essential to validate these findings in light of a
variety of methodological issues such as statistical power
and collider bias. Another confounder may be the obser-
vation that patients with the most pain are more likely to
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receive treatment. Interestingly, patients with obesity have
higher levels of pain for the same level of structural
damage [82], which suggests that they too may respond
differently to treatment. The separation into early and late
profiles does have some weight, insofar as late-stage dis-
ease, in which joint morphology is the most affected, is
best managed with surgical intervention rather than
pharmacologically.
Further research into the role of the subchondral bone is
likely to confirm the separation of patient profiles accord-
ing to subchondral bone osteopenia or sclerosis. This is
important in the light of a possible impact on response to
bone-active treatments in osteoarthritis.
Treatment decisions should be made considering clinical
presentation, underlying pathophysiology (function or
structure, the presence of inflammation, the metabolic
syndrome, adiposity, X-ray damage, functional impair-
ment, and co-morbidities), and the stage of disease (early
vs. late). In a future paper, the ESCEO group will explore
how the various therapeutic options can be expected to act
on the patient profiles in Table 2. This in turn will lead to
more personalized healthcare, with targeted treatment for
osteoarthritis.
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